NASDAQ · Biotechnology

VIVS (VIVS) Stock

$0.36 -6.54% NASDAQ: VIVS Healthcare

Valuation

MetricValue
Price$0.36
Market Cap$935751
P/E Ratio0.80
P/B Ratio0.83
P/S Ratio20.94
EPS (TTM)$1.76
52-Week High$5.30
52-Week Low$0.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-51.07%
ROA-1.33%
ROCE-118.18%
Gross Margin100.00%
Operating Margin—
Net Margin-864.08%
Debt/Equity0.13
Current Ratio3.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$2.0M$0$0$0
Operating Profit$-17.0M$-11.0M$-18.0M$-15.0M$-13.0M
Net Profit$-17.0M$-11.0M$-17.0M$-15.0M$-2.0M
EPS$-29.25$-15.78$-23.77$-19.25$-1.70
Op Margin—-765.3%-4792.2%-13840.4%-8761.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$33.0M$20.0M$6.0M$15.0M
Total Liabilities$1.0M$3.0M$5.0M$3.0M$4.0M
Cash$37.0M$29.0M$15.0M$3.0M$11.0M
Borrowings$0$2.0M$2.0M$1.0M$1.0M

Latest News

VivoSim Labs Prices $4 Million Private Placement of Stock, Warrants; Shares Fall Pre-Bell MT Newswires · Jul 16, 2026 VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor GlobeNewswire · Jul 16, 2026 VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth InvestorsHub · Jul 15, 2026 BC-Most Active Stocks Associated Press · Jul 15, 2026 VivoSim Receives $5 Million Eli Lilly Milestone Payment, Issues Fiscal 2027 Revenue Growth Outlook MT Newswires · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-8.0M$-12.0M$-15.0M$-9.0M
Investing Cash Flow$-1.0M$-1.0M$-1.0M$1.0M$9.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$10.0M$-9.0M$-13.0M$-12.0M$8.0M
Free Cash Flow$-14.0M$-9.0M$-13.0M$-15.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.96
EV / EBITDA—
FCF Yield-357.34%
Quick Ratio2.44
Interest Coverage—
Return 1Y-53.65%
Return 3Y-95.89%
Return 5Y-99.07%

Ownership

Insiders Held9.33%
Institutions Held5.74%
Institutions Float Held6.33%
Institutional HolderSharesReport Date
Geode Capital Management, LLC36,8502026-03-31
Goldman Sachs Group Inc16,0722026-03-31
Vanguard Capital Management LLC15,3712026-03-31
Blackrock Inc.11,8172026-03-31
Vanguard Fiduciary Trust Co7,0032026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About VIVS

VIVS is led by CEO Keith E. Murphy, employs 14 people, headquartered in US, publicly traded since 2012.

VIVS stock trades at $0.36 with a market capitalization of $935751. The stock is valued at a price-to-earnings (P/E) ratio of 0.80, price-to-book of 0.83, price-to-sales of 20.94. Over the past 52 weeks the stock has ranged between $0.36 and $5.30, and currently trades 93.2% below its 52-week high.

On profitability, VIVS generates a return on equity (ROE) of -51.07%, return on capital employed of -118.18%, a net profit margin of -864.08%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides